Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
138.13
-1.99 (-1.42%)
At close: Aug 6, 2025, 4:00 PM
138.13
0.00 (0.00%)
After-hours: Aug 6, 2025, 6:18 PM EDT

Company Description

Natera, Inc., a diagnostics company, provides molecular testing services worldwide.

Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test.

In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners.

It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays.

The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012.

Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Natera, Inc.
Natera logo
CountryUnited States
Founded2003
IPO DateJul 2, 2015
IndustryDiagnostics & Research
SectorHealthcare
Employees4,434
CEOSteven Chapman

Contact Details

Address:
13011 McCallen Pass, Building A
Austin, Texas 78753
United States
Phone650 980 9190
Websitenatera.com

Stock Details

Ticker SymbolNTRA
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001604821
CUSIP Number632307104
ISIN NumberUS6323071042
Employer ID01-0894487
SIC Code8071

Key Executives

NamePosition
Steven Leonard ChapmanChief Executive Officer and Director
Dr. Matthew Rabinowitz Ph.D.Co-Founder and Executive Chairman
John FeskoPresident and Chief Business Officer
Michael B. Brophy M.B.A.Chief Financial Officer
Solomon Moshkevich M.B.A.President of Clinical Diagnostics
Jonathan Sheena M.Eng.Co-Founder and Director
Olesya A. Anisimova CPAChief Accounting Officer
Rishi KackerChief Technology Officer
Eric A. Evans Ph.D.Chief Scientific Officer
Daniel Rabinowitz L.L.M.Secretary and Chief Legal Officer

Latest SEC Filings

DateTypeTitle
Aug 1, 2025144Filing
Aug 1, 2025144Filing
Aug 1, 2025144Filing
Jul 29, 2025144Filing
Jul 24, 2025144Filing
Jul 22, 2025144Filing
Jul 22, 2025SCHEDULE 13G/AFiling
Jul 1, 2025144Filing
Jul 1, 2025144Filing
Jul 1, 2025144Filing